ADXN Addex Therapeutics Ltd
USHealthcareAs of 2026-07-10 16:00
Why ADXN matters now
Addex Therapeutics Ltd (ADXN) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.34 with +7.64% on the session and $4.6M in market capitalization; recent performance reads 1-month -11.43% and YTD -19.69%.
The latest financial table shown here is Q4 2025, with revenue of $248.00, net income of $-1.8M, and EPS of $-1.54. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -31.1%.
The latest indexable market news headline is "Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $30.00; recent insider activity includes Hill Raymond George filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.38
P/S
45.67
EV/EBITDA
-0.93
DCF Value
$1.46
FCF Yield
-31.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-4.8%
Operating Margin
-1839.8%
Net Margin
-4398.5%
ROE
-102.6%
ROA
-105.8%
ROIC
-54.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $248.00 | $-1.8M | $-1.54 |
| FY 2025 | $30.0K | $-6.7M | $-6.88 |
| Q3 2025 | $29.7K | $-1.6M | $-1.67 |
| Q2 2025 | $36.4K | $-1.8M | $-2.40 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$30.00
Target (Median)
$30.00
Target Range
$30.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CH
Exchange
—
Beta
1.97
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.